OBJECTIVE: We used genetically engineered mouse hematopoietic progenitor cells (HPCs) to investigate the therapeutic effects of human apoAI on atherosclerosis in apoE(-/-) mice. METHODS AND RESULTS: Lentiviral constructs expressing either human apoAI (LV-apoAI) or green fluorescent protein (LV-GFP) cDNA under a macrophage specific promoter (CD68) were generated and used for ex vivo transduction of mouse HPCs and macrophages. The transduction efficiency was >25% for HPCs and >70% for macrophages. ApoAI was found in the macrophage culture media, mostly associated with the HDL fraction. Interestingly, a significant increase in mRNA and protein levels for ATP binding cassette A1 (ABCA1) and ABCG1 were found in apoAI-expressing macrophages after acLDL loading. Expression of apoAI significantly increased cholesterol efflux in wild-type and apoE(-/-) macrophages. HPCs transduced with LV-apoAI ex vivo and then transplanted into apoE(-/-) mice caused a 50% reduction in atherosclerotic lesion area compared to GFP controls, without influencing plasma HDL-C levels. CONCLUSIONS: Lentiviral transduction of apoAI into HPCs reduces atherosclerosis in apoE(-/-) mice. Expression of apoAI in macrophages improves cholesterol trafficking in wild-type apoE-producing macrophages and causes upregulation of ABCA1 and ABCG1. These novel observations set the stage for a cell therapy approach to atherosclerosis regression, exploiting the cooperation between apoE and apoAI to maximize cholesterol exit from the plaque.
OBJECTIVE: We used genetically engineered mouse hematopoietic progenitor cells (HPCs) to investigate the therapeutic effects of humanapoAI on atherosclerosis in apoE(-/-) mice. METHODS AND RESULTS: Lentiviral constructs expressing either humanapoAI (LV-apoAI) or green fluorescent protein (LV-GFP) cDNA under a macrophage specific promoter (CD68) were generated and used for ex vivo transduction of mouse HPCs and macrophages. The transduction efficiency was >25% for HPCs and >70% for macrophages. ApoAI was found in the macrophage culture media, mostly associated with the HDL fraction. Interestingly, a significant increase in mRNA and protein levels for ATP binding cassette A1 (ABCA1) and ABCG1 were found in apoAI-expressing macrophages after acLDL loading. Expression of apoAI significantly increased cholesterol efflux in wild-type and apoE(-/-) macrophages. HPCs transduced with LV-apoAI ex vivo and then transplanted into apoE(-/-) mice caused a 50% reduction in atherosclerotic lesion area compared to GFP controls, without influencing plasma HDL-C levels. CONCLUSIONS: Lentiviral transduction of apoAI into HPCs reduces atherosclerosis in apoE(-/-) mice. Expression of apoAI in macrophages improves cholesterol trafficking in wild-type apoE-producing macrophages and causes upregulation of ABCA1 and ABCG1. These novel observations set the stage for a cell therapy approach to atherosclerosis regression, exploiting the cooperation between apoE and apoAI to maximize cholesterol exit from the plaque.
Authors: Motonari Kondo; Amy J Wagers; Markus G Manz; Susan S Prohaska; David C Scherer; Georg F Beilhack; Judith A Shizuru; Irving L Weissman Journal: Annu Rev Immunol Date: 2002-12-17 Impact factor: 28.527
Authors: Gustavo Mostoslavsky; Attila J Fabian; Sean Rooney; Frederick W Alt; Richard C Mulligan Journal: Proc Natl Acad Sci U S A Date: 2006-10-24 Impact factor: 11.205
Authors: Steven E Nissen; Jean-Claude Tardif; Stephen J Nicholls; James H Revkin; Charles L Shear; William T Duggan; Witold Ruzyllo; William B Bachinsky; Gabriel P Lasala; Gregory P Lasala; E Murat Tuzcu Journal: N Engl J Med Date: 2007-03-26 Impact factor: 91.245
Authors: John J P Kastelein; Sander I van Leuven; Leslie Burgess; Greg W Evans; Jan A Kuivenhoven; Philip J Barter; James H Revkin; Diederick E Grobbee; Ward A Riley; Charles L Shear; William T Duggan; Michiel L Bots Journal: N Engl J Med Date: 2007-03-26 Impact factor: 91.245
Authors: Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer Journal: N Engl J Med Date: 2007-11-05 Impact factor: 91.245
Authors: Jing Liu; Hong Lu; Deborah A Howatt; Anju Balakrishnan; Jessica J Moorleghen; Mary Sorci-Thomas; Lisa A Cassis; Alan Daugherty Journal: Arterioscler Thromb Vasc Biol Date: 2015-06-04 Impact factor: 8.311
Authors: Hagai Tavori; Yan Ru Su; Patricia G Yancey; Ilaria Giunzioni; Ashley J Wilhelm; John L Blakemore; Manal Zabalawi; MacRae F Linton; Mary G Sorci-Thomas; Sergio Fazio Journal: J Lipid Res Date: 2015-01-15 Impact factor: 5.922
Authors: M C Levin; U Lidberg; P Jirholt; M Adiels; A Wramstedt; K Gustafsson; D R Greaves; S Li; S Fazio; M F Linton; S-O Olofsson; J Borén; I Gjertsson Journal: Gene Ther Date: 2011-12-01 Impact factor: 5.250
Authors: Vladimir S Shavva; Denis A Mogilenko; Ekaterina V Nekrasova; Andrey S Trulioff; Igor V Kudriavtsev; Ekaterina E Larionova; Anna V Babina; Ella B Dizhe; Boris V Missyul; Sergey V Orlov Journal: Mol Cell Biochem Date: 2018-02-13 Impact factor: 3.396
Authors: Terry L Lewis; Dongfeng Cao; Hailin Lu; Robert A Mans; Yan Ru Su; Lisa Jungbauer; MacRae F Linton; Sergio Fazio; Mary Jo LaDu; Ling Li Journal: J Biol Chem Date: 2010-09-16 Impact factor: 5.157
Authors: Rowan Flynn; Kun Qian; Chongren Tang; Nagadhara Dronadula; Joshua M Buckler; Bo Jiang; Shan Wen; Helén L Dichek; David A Dichek Journal: Mol Ther Date: 2011-07-19 Impact factor: 11.454